Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Investment analysts at HC Wainwright increased their FY2025 EPS estimates for shares of Cassava Sciences in a research note issued on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($0.55) for the year, up from their previous forecast of ($0.62). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Cassava Sciences' current full-year earnings is ($3.97) per share.
Cassava Sciences Price Performance
Shares of Cassava Sciences stock traded down $0.09 during trading on Friday, hitting $2.58. The stock had a trading volume of 868,213 shares, compared to its average volume of 2,848,196. The business has a fifty day moving average of $2.56 and a two-hundred day moving average of $14.34. Cassava Sciences has a fifty-two week low of $2.23 and a fifty-two week high of $42.20. The firm has a market cap of $124.63 million, a P/E ratio of -1.87 and a beta of -1.24.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.11.
Hedge Funds Weigh In On Cassava Sciences
Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in Cassava Sciences by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,008,593 shares of the company's stock worth $29,688,000 after buying an additional 41,289 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Cassava Sciences by 150.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,748 shares of the company's stock worth $257,000 after acquiring an additional 5,250 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Cassava Sciences in the 3rd quarter worth $373,000. KBC Group NV acquired a new stake in shares of Cassava Sciences during the third quarter worth $57,000. Finally, Tidal Investments LLC acquired a new stake in shares of Cassava Sciences during the third quarter worth $11,036,000. Institutional investors own 38.05% of the company's stock.
Cassava Sciences Company Profile
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
